ACP-105

Overview

ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the androgen receptor with tissue-selective anabolic effects demonstrated in preclinical models. ACP-105 is not an approved drug in any jurisdiction and has never entered human clinical trials. SARMs as a class are prohibited at all times under WADA Prohibited List S1.2 'Other Anabolic Agents'; ACP-105 falls under this class-wide ban and has been the subject of equine anti-doping metabolite-detection research.

Mechanism of Action

ACP-105 is a nonsteroidal partial agonist at the androgen receptor (AR), discovered via receptor selection and amplification (R-SAT) high-throughput screening. It exhibits partial agonist activity relative to testosterone with tissue-selective anabolic effects, demonstrating potent and selective AR agonism in cell-based assays. No human receptor-binding or clinical pharmacology data exist; all mechanistic characterization is derived from in vitro assays and rodent models.

Research Summary

No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.

Vendors selling ACP-105

Scored vendors carrying ACP-105, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• No human safety data exist
• No validated human dose or GLP toxicology package publicly available
• Prohibited under WADA S1.2 (SARMs class-wide ban)
• Gray-market products may be mislabeled for identity/quantity (class-level SARM finding)
• Class-level SARM concerns (hepatic, lipid, endocrine effects) not ACP-105-specific

Compare ACP-105 with Others

Research References

• Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. 2009. PMID 19856921.
• In vitro and in vivo profile of a novel tissue selective, orally bioavailable non-steroidal androgen receptor modulator (ACP-105). 2008.
• Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice. 2011. PMID 21219889.
• Nonsteroidal selective androgen receptor modulators and selective estrogen receptor beta agonists moderate cognitive deficits and amyloid-beta levels in a mouse model of Alzheimer's disease. 2013. PMID 24020966.

Frequently asked questions

Has ACP-105 been independently lab-tested?

Disclosed Labs has collected 2 Certificates of Analysis (COA) for ACP-105 from 1 independent testing lab. 1 vendor has submitted material for testing. Products average 99.3% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/acp-105/testing.

Where can researchers source ACP-105?

1 vendor with Disclosed Labs trust grades currently list ACP-105, including Kimera Chems. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/acp-105.

How does ACP-105 work?

ACP-105 is a nonsteroidal partial agonist at the androgen receptor (AR), discovered via receptor selection and amplification (R-SAT) high-throughput screening. It exhibits partial agonist activity relative to testosterone with tissue-selective anabolic effects, demonstrating potent and selective AR agonism in cell-based assays. No human receptor-binding or clinical pharmacology data exist; all mechanistic characterization is derived from in vitro assays and rodent models.

What does the research say about ACP-105?

No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.